<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211259</url>
  </required_header>
  <id_info>
    <org_study_id>011910</org_study_id>
    <secondary_id>NCI-2019-07795</secondary_id>
    <secondary_id>Pro2019001846</secondary_id>
    <secondary_id>011910</secondary_id>
    <secondary_id>P30CA072720</secondary_id>
    <nct_id>NCT04211259</nct_id>
  </id_info>
  <brief_title>Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization</brief_title>
  <official_title>The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well loratadine works in reducing granulocyte-colony
      stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are
      undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or
      control bone pain during the process of stem cell collection in patients with multiple
      myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To evaluate the efficacy of the second-generation antihistamine, loratadine, as
      prophylaxis for filgrastim (i.e., Neupogen, Zarxio) induced bone pain during stem cell
      mobilization in multiple myeloma patients.

      SECONDARY OBJECTIVES:

      I. To examine the frequency and quantity of supportive analgesic medications needed in
      addition to loratadine or placebo for filgrastim induced bone pain.

      II. To identify risk factors associated with developing filgrastim induced bone pain.

      OUTLINE: Patients are randomized to 1 of 2 cohorts.

      COHORT I: Beginning 5 days before the first dose of standard of care filgrastim, patients
      receive loratadine orally (PO) once daily (QD). Treatment continues until 5 days after
      completion of stem cell mobilization in the absence of disease progression or unacceptable
      toxicity.

      COHORT II: Beginning 5 days before the first dose of standard of care filgrastim, patients
      receive placebo PO QD. Treatment continues until 5 days after completion of stem cell
      mobilization in the absence of disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pain level for each group following therapy</measure>
    <time_frame>Baseline up to 5 days after completion of stem cell mobilization</time_frame>
    <description>Pain severity will be measured at baseline and following treatment using a 10-point scale, with higher numbers indicating greater degrees of pain. Will compare the difference in mean pain level for each group following therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort I (loratadine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort I (loratadine)</arm_group_label>
    <other_name>Claritin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Cohort I (loratadine)</arm_group_label>
    <arm_group_label>Cohort II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be able to provide informed consent

          -  Patients with confirmed diagnosis of multiple myeloma

          -  Able to swallow and retain oral medication

          -  All ethnic groups are eligible

        Exclusion Criteria:

          -  Non-English speaking person

          -  Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant

          -  Known allergies, hypersensitivity, or intolerance to any of the study medications,
             excipients, or similar compounds

          -  Any medical complications or conditions that would, in the investigator's judgement,
             interfere with full participation in the study

          -  On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the
             start of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis L Cooper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dennis L. Cooper</last_name>
      <phone>732-235-4251</phone>
      <email>dc1073@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Dennis L. Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers Cancer Institute of New Jersey</investigator_affiliation>
    <investigator_full_name>Dennis L. Cooper</investigator_full_name>
    <investigator_title>Chief, Section of Blood &amp; Marrow Transplantation Program Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

